GlassScriptPhysician profile
Peter J Matthews
NPI 1184625832
$2,788.94
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,538 · 2020: $489 · 2021: $761.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,234.83 | 2019-2020 | |
| Pfizer INC. | $408.31 | 2019-2021 | |
| Astellas Pharma US INC | $281.31 | 2019-2021 | |
| Boston Scientific Corporation | $143.14 | 2019-2021 | |
| Abbvie INC. | $127.43 | 2020-2021 | |
| Clarus Therapeutics INC. | $101.95 | 2021 | |
| Coloplast Corp | $62.63 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.47 | 2020-2021 | |
| Allergan, INC. | $48.83 | 2020-2021 | |
| C. R. Bard, INC. & Subsidiaries | $47.65 | 2019-2020 | |
| Janssen Biotech, INC. | $40.76 | 2021 | |
| Axonics, INC. | $38.13 | 2021 | |
| Antares Pharma, INC. | $37.70 | 2019 | |
| Hollister Incorporated | $34.03 | 2021 | |
| Smith+Nephew, INC. | $31.64 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $30.91 | 2020 | |
| Dentsply Ih INC. | $28.40 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $16.64 | 2019 | |
| Endo Pharmaceuticals INC. | $12.18 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.